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Orexins (also known as hypocretins) play critical roles in the regulation of
sleep/wakefulness states by activating two G-protein coupled receptors (GPCRs),
orexin 1 (OX1R) and orexin 2 receptors (OX2R). In order to understand the differential
contribution of both receptors in regulating sleep/wakefulness states we compared the
pharmacological effects of a newly developed OX2R antagonist (2-SORA), Compound
1m (C1m), with those of a dual orexin receptor antagonist (DORA), suvorexant, in
C57BL/6J mice. After oral administration in the dark period, both C1m and suvorexant
decreased wakefulness time with similar efficacy in a dose-dependent manner. While C1m
primarily increased total non-rapid eye movement (NREM) sleep time without affecting
episode durations and with minimal effects on REM sleep, suvorexant increased both
total NREM and REM sleep time and episode durations with predominant effects on
REM sleep. Fos-immunostaining showed that both compounds affected the activities
of arousal-related neurons with different patterns. The number of Fos-IR noradrenergic
neurons in the locus coeruleus was lower in the suvorexant group as compared with
the control and C1m-treated groups. In contrast, the numbers of Fos-IR neurons in
histaminergic neurons in the tuberomamillary nucleus and serotonergic neurons in the
dorsal raphe were reduced to a similar extent in the suvorexant and C1m groups
as compared with the vehicle-treated group. Together, these results suggest that an
orexin-mediated suppression of REM sleep via potential activation of OX1Rs in the locus
coeruleus may possibly contribute to the differential effects on sleep/wakefulness exerted
by a DORA as compared to a 2-SORA.
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INTRODUCTION
A series of studies have suggested that loss of hypothala-
mic neurons producing orexin (orexin neurons) causes nar-
colepsy in humans and other mammalian species, showing that
orexin plays an extremely important role in the regulation of
sleep/wakefulness states, especially in the maintenance of wake-
fulness (Sakurai and Mieda, 2011). Because orexin is an arousal-
promoting factor, it is reasonable to hypothesize that orexin
receptor antagonists will be effective as drugs for the treatment
of insomnia. Indeed, several orexin receptor antagonists with dif-
ferent pharmacological characteristics are under development as
next generation sleep-inducing drugs.
A dual orexin receptor antagonist (DORA), almorexant (ACT-
078573), blocks both OX1R and OX2R with similar potency
(IC50 16 and 15 nM, respectively). Almorexant was reported
to shorten the time spent awake and maintain sleep in rats,
dogs, and humans (Brisbare-Roch et al., 2007; Hoever et al.,
2010). Almorexant significantly improved the primary parameter
of sleep efficiency in humans (time spent sleeping while con-
fined to bed during an 8 h period at night) in a dose-dependent
manner. Almorexant decreased the latency to sleep onset and
the number of wakefulness bouts after sleep onset. Importantly,
almorexant not only changed these physiological sleep param-
eters, but also significantly improved subjective sleep quality.
Effective or even higher doses of almorexant did not cause any
significant negative effects on next-day performance (assessed
by fine motor testing and mean reaction time). In addition, it
was reported that rats administered a high dose of almorex-
ant (300mg/kg, p.o.) were fully capable of spatial and avoidance
learning (Dietrich and Jenck, 2010). Notably, almorexant was
well tolerated with no sign of cataplexy, suggesting that acute,
short-lived, intermittent temporary blockade of orexin recep-
tors will not result in a narcolepsy-like phenotype (Neubauer,
2010).
Phase III clinical trials of suvorexant (MK-4305), a DORA
developed by Merck & Co., for the modulation of sleep have
been completed (Cox et al., 2010). Suvorexant is a potent
DORA with excellent potency in cell-based calcium mobilization
assays (OX1R IC50 = 50 nM, OX2R IC50 = 56 nM) (Winrow and
Renger, 2013). Recent studies showed that patients taking the
drug fell asleep faster and slept longer than those on placebo,
with nomajor adverse effects (Hopkins, 2012; Mieda and Sakurai,
www.frontiersin.org January 2014 | Volume 8 | Article 8 | 1
Etori et al. Effects of orexin-2 receptor-selective antagonist
2013). Suvorexant is expected to be available for clinical use
in 2014.
Recently, administration of a selective OX2R antagonist
(2-SORA), JNJ-10397049, in rats was also shown to decrease
the latency to persistent sleep and to increase NREM sleep time
more potently than did almorexant (Dugovic et al., 2009), while
a selective OX1R antagonist, SB-408124, had no effect on sleep
parameters. Rather, SB-408124 attenuated the sleep-promoting
effects of the OX2R antagonist when simultaneously adminis-
tered, possibly by increasing dopamine release in the prefrontal
cortex. However, the effectiveness of DORA and 2-SORA is a con-
troversial issue, because another report suggested that almorexant
is more effective for sleep promotion than is antagonism of
either receptor alone (Morairty et al., 2012). Further research
using selective antagonists with different pharmacological char-
acteristics is required to reach a conclusion on the effectiveness,
advantages and disadvantages of these compounds.
In this study, we compared the effects of a newly-developed
potent OX2R-selective antagonist (2-SORA), Compound 1m
(C1m), with those of suvorexant. C1m showed potent OX2R
antagonistic activity (IC50 27 nM) and good selectivity against
OX1R (IC50 3000 nM, determined by cell-based calcium mobi-
lization assay using receptor-expressing cells). C1m is an
amphiphilic molecule simultaneously possessing high water sol-
ubility and lipophilicity, to which its good oral availability is
attributable (Fujimoto et al., 2011). Furthermore, this compound
showed excellent metabolic stability in human and rat liver
microsomes (Fujimoto et al., 2011).
We found C1m had comparable efficacy to that of suvorex-
ant in increasing NREM sleep time, but showed little effect on
REM sleep amount, while suvorexant significantly increased REM
sleep. Suvorexant induced longer NREM and REM sleep episode
durations as compared with C1m. Suvorexant and C1m affected
the number of Fos-positive monoaminergic neurons in the brain
stem with differential patterns. These results suggest differential
roles of OX1R and OX2R in sleep/wakefulness regulation.
MATERIALS AND METHODS
ANIMALS
All mice used in this study had a C57B6/J genetic background
and were 12–15 weeks of age and weighed 25–30 g. They were
fed ad libitum and housed under conditions where tempera-
ture (22◦C) and humidity were controlled with a 12-h light/dark
cycle (lights on at 8:45 a.m., off at 8:45 p.m.). All experimen-
tal procedures were approved by the Animal Experimental and
Use Committee of Kanazawa University (AP-132649) and were in
accordance with NIH guidelines. All efforts were made to mini-
mize animal suffering and discomfort and to reduce the number
of animals used.
SUBSTANCES AND ADMINISTRATION
C1m, a novel potent 2-SORA, was provided by Takeda
Pharmaceutical, Co., Ltd. (Japan) (Fujimoto et al., 2011). A
DORA, [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-
diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]metha
none (suvorexant) was synthesized according to a previously
reported procedure (Cox et al., 2010) (lot # 130301, NARD
Institute, Amagasaki, Japan). Drugs were suspended in 1%
methylcellulose (Sigma) and administered to mice per os using a
disposable feeding needle (Fuchigami Kikai, Japan) at Zeitgeber
time (ZT) 12 or ZT0.
SLEEP RECORDINGS
Mice were anesthetized with sodium pentobarbital, and an elec-
trode was implanted for EEG/EMG recording. Four holes were
drilled in the skull, and the arms of the electrode for EEG were
implanted at sites approximately 2mm anterior, ± 2mm lat-
eral, and 2mm posterior to the bregma. EMG recording wires
made of stainless steel were inserted into the neck muscles bilat-
erally. Each electrode was fixed rigidly to the skull with dental
cement (ESPE Ketac-Cem). After the recovery period (5–6 days
after surgery), mice were moved to a recording cage placed in an
electrically shielded and sound-attenuated room. The implanted
electrode of each mouse was connected to a cable for signal
output. They were allowed to move freely with access to food
and water ad libitum. Signals were amplified through an ampli-
fier (AB-611J, Nihon Koden, Tokyo) and digitally recorded on
a computer using EEG/EMG recording software (Vital recorder,
Kissei Comtec). Mice were put in recording cages for at least 7
days to allow them to adapt to the recording conditions prior to
any EEG/EMG recording session. Following the acclimatization
period, 1% methylcellulose as control, C1m and suvorexant were
orally administered to mice on separate experimental days with
an interval of at least 3 days. Each dose of drugs was explored in
different groups of mice (n = 5–9/group). We did not use mice
repeatedly, in order to avoid the influences of repeated admin-
istration procedures and residual effects of drugs. EEG/EMG
data for 24 h following drug administration were evaluated as
previously described (Hara et al., 2001).
STATISTICAL ANALYSIS
Data were expressed as mean ± s.e.m. Two-Way analysis of vari-
ance (ANOVA) followed by Bonfferoni correction as a post-hoc
test or Student’s t-test using GraphPad Prism 6.01 was used for
comparison among the various treatment groups. Differences
were considered significant at p < 0.05.
IMMUNOHISTOCHEMISTRY
Mice were anesthetized deeply and perfused with 60ml ice-cold
phosphatebuffersaline(PBS)and40mlice-cold4%paraformalde-
hyde (PFA) in0.1Mphosphatebuffer2 hafterdrugadministration
at ZT12. The brainwas removed and immersed in 4%PFA for 24 h
at 4◦C, and then in 30% sucrose in 0.1MPBS for 2 days. The brain
wasthenfrozenquickly inembeddingsolution(SakuraFinetekCo.,
Ltd., Tokyo, Japan) and cut into coronal sections (30-µm thick)
using a cryostat (HM505E,Micron,Walldorf, Germany). Coronal
brain sections were washed three times for 10min in 0.1M PBS
containing 1% bovine serum albumin and 0.25% Triton-X-100
(PBS-BX). To detect Fos-like immunoreactivity (IR) in orexin-
expressing neurons, the sections were incubated overnight at 4◦C
with guinea pig anti-orexin antibody (1:500) and rabbit anti-cFos
antibody Ab-5 (Calbiochem, 1:10,000). After washing three times
with PBS-BX, tissue was incubated for 1 h with Alexa Fluor 594-
goat anti-guinea pig IgG (Molecular Probes, 1:800) and Alexa
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Fluor 488-goat anti-rabbit IgG (Molecular Probes, 1:800) and
then washed three times again. The sections were mounted on
glass slides and cover-slipped, and the slides were examined by
laser-confocal microscopy (Olympus FV10i).
To detect Fos-IR in serotonergic, histaminergic, and nora-
drenergic neurons, coronal brain sections were incubated with
mouse anti-tryptophan hydroxylase (TPH) antibody (Santa Cruz
Biotech, 1:200), guinea pig anti-histidine decarboxylase (HDC)
antibody (PROGEN Biotechnik Gmbh, 1:4000), or mouse anti-
tyrosine hydroxylase (TH) antibody (Santa Cruz Biotech, 1:2000),
respectively, with rabbit anti-Fos antibody Ab-5 (Calbiochem,
1:10,000). As a second antibody, Alexa Fluor 594-goat anti-mouse
IgG (Molecular Probes, 1:800), Alexa Fluor 594-goat anti-guinea
pig IgG (Molecular Probes, 1:800), or Alexa Fluor 488-goat anti-
rabbit IgG (Molecular Probes, 1:800) was used.
RESULTS
C1m INCREASED NREM SLEEP TIME WITHOUT AFFECTING REM
SLEEP TIME
To examine the effect of C1m on sleep/wakefulness states, we
administered it orally to mice at the start of the dark period.
Mice administered C1m (30 and 90mg/kg) showed significantly
shorter wakefulness time as compared with vehicle-administered
mice for 6 h after administration (Figure 1A, Figure S1A).
Wakefulness time for 6 h post-administration was 17.2 and 22.6%
shorter in the 30 and 90mg/kg C1m groups, respectively, as com-
pared to that in the control group [F(3, 26) = 9.55, p < 0.001]
(Figure 1A). Hourly analysis suggested that the effect lasted for
5 h (Figure S1A). The decrease of wakefulnes was accompanied
by a dose-dependent increase of NREM sleep time (Figure 1B,
Figure S1B), which was significant during the 6 h after admin-
istration [F(3, 26) = 8.54, p < 0.01 for 30mg/kg, p < 0.001 for
90mg/kg] (Figure 1B). Importantly, no significant difference
in total REM sleep time was observed between the C1m and
vehicle groups, although there was a weak tendency for C1m
to increase total REM sleep tine (Figure 1C, Figure S1C). The
C1m-administered group showed shorter wakefulness episode
durations as compared with the vehicle-treated group [F(3, 26) =
5.39, p < 0.05 for 30mg/kg, p < 0.01 for 90mg/kg] (Figure 1D).
NREM and REM sleep episode durations were not affected by
C1m (Figures 1E,F, Figures S1E,F).
Latency to NREM sleep onset after administration of C1m
show a tendency to be shorter than that in the control group,
but the difference was not statistically significant (Figure 1G).
Latency to the onset of REM sleep after administration was
not significantly different between the C1m- and vehicle-
administered groups (Figure 1H). The power density of EEG
in the C1m-administered group (30 and 90mg/kg) showed no
difference from that in the vehicle-administered group, specif-
ically in regard to NREM delta power (0.5–4Hz) (Figure 1I).
However, we observed decrease in slow wave power in the low
dose (10mg/kg) group [F(40, 246) = 2.547, p < 0.01 for 1Hz,
p < 0.001 for 2.5Hz] (Figure 1I).
We next administered C1m just prior to the start of the light
period (ZT0). The total wakefulness and NREM sleep times
were not significantly different between the C1m and vehicle
groups during the light period (Figures 2A,B, Figures S2A,B).
REM sleep time for 6 h after the administration in the low dose
C1m group (10mg/kg) was shorter as compared with the con-
trol group, suggesting that low dose of C1m rather shortens REM
sleep time (Figure 2C, Figure S2C). Wakefulness episode dura-
tion was also not affected by C1m (Figure 2D). However, NREM
and REM sleep episode durations were significantly shorter in
the C1m groups (30 and 10mg/kg) than in the control group
(Figures 2E,F, Figures S2E,F). Latencies to NREM and REM
sleep onset after administration of C1mwere not significantly dif-
ferent from that in the control group (Figures 2G,H). The power
density of EEG in the C1m-administered groups showed no dif-
ference from that in the vehicle-administered group in NREM
sleep (Figure 2I).
SUVOREXANT DECREASED WAKEFULNESS TIME AND INCREASED
BOTH NREM AND REM SLEEP TIMES
To compare the effect of C1m with that of a DORA, we also
examined the effect of suvorexant, a DORA, on sleep/wakefulness
states of mice under the same recording condition. Mice admin-
istered suvorexant (30mg/kg) at the start of the dark period
showed a significantly shorter wakefulness time as compared
with vehicle-administered mice for 6 h after administration
(Figure 3A, Figure S3A). The wakefulness time for 6 h post-
administration of suvorexant (30mg/kg) was shortened by 17.8%
[F(2, 20) = 3.74, p < 0.05] (Figure 3A). This effect was accompa-
nied by increases of both NREM and REM sleep time (Figure 3C,
Figures S3B,C). Significant differences were also observed in
the latter half of the dark period; wakefulness time was rather
longer and NREM and REM sleep times were shorter in the
suvorexant group than in the control group in this time win-
dow (Figures 3A–C, Figures S3A–C). These effects are likely to
be the rebound of wakefulness due to homeostatic mechanisms
controlling the amount of sleep.
Episode durations of wakefulness and NREM sleep in the
suvorexant group for 6 h after administration were not different
from those in the control group (Figures 3D,E, Figures S3D,E).
However, there were significant differences in these parameters
in the latter half of the dark period between the suvorexant
and control groups [Wakefulness episodes: F(2, 20) = 10.58, p <
0.01 for 10mg/kg, p < 0.001 for 30mg/kg, Figure 3D] [NREM
sleep episodes: F(2, 20) = 4.86, p < 0.05 for 10mg/kg, p < 0.05
for 90mg/kg, Figure 3E]. The longer episode duration of NREM
sleep in the suvorexant group continued in the subsequent light
period. These observations suggest that suvorexant consolidates
both wakefulness and NREM sleep episodes. REM sleep episode
duration was not significantly affected by suvorexant for 12 h after
administration (Figure 3F). However, hourly analysis showed
that high dose (30mg/kg) suvorexant increased REM sleep dura-
tion for several hours (Figure S3F). Latency to NREM sleep onset
after administration of C1m showed a tendency to be shorter
than that in the control group, although the difference was
not statistically significant (Figure 3G). REM sleep latency after
administration was shorter in the 30mg/kg group than in the
vehicle group during the dark period [F(2, 20) = 4.92, p < 0.05]
(Figure 3H).
The power density of EEG in the suvorexant-administered
group (30mg/kg) showed slightly, but significantly larger percent
of 0.5 and 2.5Hz component [F(40, 246) = 2.539, p < 0.0001 for
0.5Hz, p < 0.05 for 2.5Hz] (Figure 3I).
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FIGURE 1 | Effects of C1m on basal sleep/wakefulness states in C57BL/6
mice (n = 6–9/group) after administration at start of dark period. C1m
(10, 30, 90mg/kg) and methylcellulose as control were administered per os at
the start of the light period (t = 0, ZT = 12). (A–C) Total time spent in
wakefulness (A), NREM sleep (B), and REM sleep (C) in 6 h time windows
over 24 h. (D–F) Mean duration of wakefulness (D), NREM sleep (E) and
REM sleep (F) in 6 h time windows over 24 h. Data for the dark and light
periods are displayed with light gray and white backgrounds, respectively.
(G,H) Latency to NREM sleep (time to appearance of first NREM sleep after
administration) (G) and REM sleep latency (time to appearance of first REM
sleep after administration) (H) during dark period. Results are expressed in
minutes and presented as mean ± s.e.m. (I) EEG power density during
NREM sleep for 3 h after administration shown as mean percentage of total
EEG power. The delta range (0.75–4Hz) is indicated by the black bar and the
theta range (6–9Hz) by the gray bar. ∗p < 0.05 for 10mg/kg C1m, +p < 0.05
for 30mg/kg C1m, #p < 0.05 for 90mg/kg C1m vs. control.
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FIGURE 2 | Effects of C1m on basal sleep/wakefulness states in C57BL/6
mice (n = 6–7/group) after administration at start of light period. C1m
(10, 30, 90mg/kg) and methylcellulose as control were administered per os at
the start of the light period (t = 0, ZT = 0). (A–C) Total time spent in
wakefulness (A), NREM sleep (B), and REM sleep (C) in 6 h time windows
over 24 h. (D–F) Mean duration of wakefulness (D), NREM sleep (E) and
REM sleep (F) in 6 h time windows over 24 h. Data for the dark and light
periods are displayed with light gray and white backgrounds, respectively.
(G,H) Latency to NREM sleep (time to appearance of first NREM sleep after
administration) (G) and REM sleep latency (time to appearance of first REM
sleep after administration) (H) during light period. Results are expressed in
minutes and presented as mean ± s.e.m. (I) EEG power density during
NREM sleep for 3 h after administration shown as mean percentage of total
EEG power. The delta range (0.75–4Hz) is indicated by the black bars and the
theta range (6–9Hz) by the gray bars.∗p < 0.05 for 10mg/kg C1m, +p < 0.05
for 30mg/kg C1m, #p < 0.05 for 90mg/kg C1m vs. control.
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FIGURE 3 | Effects of DORA, suvorexant, on basal sleep/wakefulness
states in C57BL/6 mice (n = 7–9/group) after administration at ZT12.
Suvorexant (10 and 30mg/kg) and methylcellulose as control were
administered per os at the start of the dark period (t = 0, ZT12). (A–C) Total
time spent in wakefulness (A), NREM sleep (B) and REM sleep (C) in 6 h
time windows over 24 h. (D–F) Mean duration of wakefulness (D), NREM
sleep (E) and REM sleep (F) in 6 h time windows over 24 h. Data for the dark
and light periods are displayed with light gray and white backgrounds,
respectively. (G,H). Latency to NREM sleep (time to appearance of first
NREM sleep after administration) (G) and REM sleep latency (time to
appearance of first REM sleep after administration) (H) during dark period.
Results are expressed in minutes and presented as mean ± s.e.m. (I) EEG
power density during NREM sleep for 3 h after administration shown as
mean percentage of total EEG power. The delta range (0.75–4Hz) is indicated
by the black bars and the theta range (6–9Hz) by the gray bars. ∗p < 0.05 for
10mg/kg suvorexant, +p < 0.05 for 30mg/kg suvorexant vs. control.
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Mice administered suvorexant (30mg/kg) at the start of light
period showed a shorter wakefulness time and longer REM sleep
time after administration as compared with vehicle-administered
mice (Figures 4A–C, Figures S4A–C). During the light phase,
suvorexant showed an effect on wakefulness for 1 h and on REM
sleep for 3 h (Figures S4A–C). Wakefulness and NREM sleep
episode durations were not affected by suvorexant administration
(Figures 4D,E). However, REM sleep episode duration was longer
in the suvorexant group. This effect lasted for 24 h (Figure 4F).
NREM and REM sleep latencies were not different statistically
betweenthesuvorexantandvehiclegroups(Figure 4H).Thepower
density of EEG in the suvorexant-administered group showed no
difference fromthat in thevehicle-administeredgroup(Figure 4I).
COMPARISON OF EFFECTS OF C1m vs. SUVOREXANT
Considering the differences in the effective time periods of action
of both compounds, we also compared the effects of these drugs
in the time window of 2 or 3 h after administration (Figure 5,
Table 1).
For 2 h after administration at ZT12, both C1m and suvorex-
ant increased NREM sleep time [F(5, 38) = 5.33, p < 0.05 for
C1m 30mg/kg, p < 0.05 for C1m 90mg/kg, p < 0.01 for
suvorexant 30mg/kg] (Figure 5B). There was a major difference
in the effect on REM sleep time: C1m showed little effect on
REM sleep time even at a high dose (90mg/kg), while suvorex-
ant (30mg/kg) markedly increased REM sleep time [F(5, 38) =
14.06, p < 0.0001] (Figure 5C). There was also a difference in
the effects of both compounds on each episode duration. Both
C1m and suvorexant shortened the wakefulness episode duration
in a dose-dependent manner [F(5, 38) = 4.08, p < 0.05 for C1m
30mg/kg, p < 0.01 for C1m 90mg/kg, p < 0.05 for suvorexant
30mg/kg] (Figure 5D). C1m did not change the NREM sleep or
REM sleep episode durations (Figures 1E,F), whereas suvorex-
ant (30mg/kg) increased both the REM [F(5.38) = 3.76, p < 0.05]
and NREM sleep [F(5, 38) = 5.74, p < 0.01] episode durations
(Figures 5E,F).
While C1m increased the transition numbers of both wakeful-
ness to NREM sleep and NREM sleep to wakefulness, suvorexant
did not show any effects on these parameters (Table 1). On the
other hand, suvorexant increased NREM to REM sleep and REM
to wakefulness transitions, while C1m did not influence them
(Table 1).
EFFECTS OF C1m AND SUVOREXANT ON ACTIVITY OF OREXINERGIC,
NORADRENERGIC, SEROTONERGIC, AND HISTAMINERGIC NEURONS
To define the effects of C1m and suvorexant on activity of
arousal-related neurons, we examined Fos-like immunoreactiv-
ity (Fos-IR) in orexin neurons, noradrenergic neurons in the
locus coeruleus (LC), serotonergic neurons in the dorsal raphe
(DR) nucleus, and histaminergic neurons in the tuberomammil-
lary nucleus (TMN). Since Fos-IR generally reflects the activity of
neurons for 60–90min before the time of fixation, we killed mice
2 h after drug administration. Mice were administered drugs at
ZT12, and killed at ZT14.
Whereas the numbers of Fos-positive orexin neurons and
noradrenergic neurons were not affected by C1m, suvorex-
ant significantly increased the number of Fos-positive orexin
neurons (Control, 67.0 ± 2.5%; suvorexant, 88.0 ± 1.3%,
[F(2, 15) = 8.90, p < 0.01] and decreased the number of
Fos-positive noradrenergic neurons [Control, 74.9 ± 2.8%;
suvorexant, 57.5 ± 3.6%, F(2, 15) = 17.65, p < 0.01)]
(Figures 6A,B). C1m (30mg/kg) administration significantly
decreased the numbers of Fos-positive serotonergic neurons
[Control, 44.1 ± 3.9%; C1m, 20.3 ± 5.0%, F(2, 15) = 13.21,
p < 0.01] and histaminergic neurons [Control, 48.7 ± 6.9%;
C1m, 24.3 ± 7.4%, F(2, 15) = 7.57, p < 0.05] (Figures 6C,D).
Similarly, suvorexant (30mg/kg) significantly decreased the
numbers of Fos-positive serotonergic neurons [Control, 44.1 ±
3.9%; suvorexant, 19.1 ± 2.2%, F(2, 15) = 13.21, p < 0.01] and
histaminergic neurons [Control, 48.7 ± 6.9%; suvorexant, 15.8 ±
3.5%, F(2, 15) = 7.57, p < 0.01] (Figures 6C,D).
DISCUSSION
Orexin receptor antagonists, especially DORAs, are under devel-
opment as next generation drugs for treating insomnia. Precise
knowledge about differential roles of the two orexin receptors
would be beneficial for application of orexin agonists/antagonists
as treatment for various diseases. It has been thought that OX2R
plays a pivotal role in the maintenance of wakefulness, based
on the phenotype of receptor-deficient mice and pharmacolog-
ical studies using these mice (Sakurai and Mieda, 2011). OX2R
knockout mice show characteristics of narcolepsy (Willie et al.,
2003), while OX1R knockout mice show an almost normal sleep-
wake cycle (Willie et al., 2001). However, the phenotype of OX2R
knockout mice is less severe than that found in prepro-orexin
knockout mice and double receptor knockout mice. Especially,
OX2R knockout mice are almost 33 times less affected by cata-
plexy and direct transitions to REM sleep from an awake state
as compared with orexin ligand knockout mice (Willie et al.,
2003). Furthermore, the effects of orexin A on wakefulness and
NREM sleep were significantly attenuated in OX2R−/− mice as
compared with wild-type mice and OX1R−/− mice, although
OX1R−/− mice showed a slightly impaired response (Mieda
et al., 2011). Notably, suppression of REM sleep by orexin-A
administration was similarly attenuated in both OX1R−/− and
OX2R−/− mice, suggesting a comparable contribution of the two
receptors to REM suppression. These observations suggest that
although the OX2R-mediated pathway has a pivotal role in the
promotion of wakefulness, OX1R also has additional effects on
sleep/wakefulness regulation, especially in the inhibitory regula-
tion of REM sleep.
In this study, we examined the effect of a novel 2-SORA, C1m,
in mice. We found that C1m (30 and 90mg/kg) significantly
reduced wakefulness time along with an increase in NREM sleep
time for 5 h after administration at the start of the dark period
(Figures 1A,B). The efficacy of C1m in increasing NREM sleep
time was comparable (Figure 5B) or even stronger (Figures 1B,
3B) than that of suvorexant, depending on the observation time.
This indicates that the sole blockade of OX2R is sufficient to
increase NREM sleep time. This is consistent with a previous
pharmacological study suggesting that wakefulness/NREM sleep
transition depends primarily on OX2R (Mieda et al., 2011).
However, while suvorexant increased the NREM sleep episode
duration, C1m did not (Figure 5E). Likewise, C1m increased the
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FIGURE 4 | Effects of suvorexant on basal sleep/wakefulness states in
C57BL/6 mice (n = 5–7/group) after administration at start of light
period. Suvorexant (10 and 30mg/kg) and methylcellulose as control were
administered per os at the start of the recording (t = 0, ZT0). (A–C) Total time
spent in waking (A), NREM sleep (B) and REM sleep (C) in 6 h time windows
over 24 h. (D–F) Mean duration of wakefulness (D), NREM sleep (E), and
REM (F) sleep in 6 h time windows over 24 h. Data for the dark and light
periods are displayed with light gray and white backgrounds, respectively.
(G,H) Latency to NREM sleep (time to appearance of first NREM sleep after
administration) (G) and REM sleep latency (time to appearance of first REM
sleep after administration) (H) during light period. Results are expressed in
minutes and presented as mean ± s.e.m. (I) EEG power density during
NREM sleep for 3 h after administration shown as mean percentage of total
EEG power. The delta range (0.75–4Hz) is indicated by the black bars and the
theta range (6–9Hz) by the gray bars. ∗p < 0.05 for 10mg/kg suvorexant,
+p < 0.05 for 30mg/kg suvorexant vs. control.
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FIGURE 5 | Total time (A–C) and average episode duration (D–F) of
awake (A,D), NREM sleep (B,E) and REM sleep (C,F) states for
the first 2 h after administration of suvorexant or C1m at ZT12,
compared with vehicle-administered group. Data are expressed as
percentage and presented as mean ± s.e.m. (n = 6–9/group).
∗p < 0.05; ∗∗p < 0.01 and ∗∗∗∗p < 0.0001.
Table 1 | Total number of state transitions after administration of Compound 1m (10, 30, and 90mg/kg) and Suvorexant (10 and 30mg/kg) in
wild-type mice at ZT 12.
Vehicle Compound 1m Suvorexant
(n = 6) 10mg/kg (n = 6) 30mg/kg (n = 9) 90mg/kg (n = 6) 10mg/kg (n = 7) 30mg/kg (n = 7)
W → NR 25.2 (2.8) 28.0 (5.0) 41.8 (6.8)* 44.7 (5.3)* 22.7 (2.4) 30.4 (1.7)
W → R 0 0 0 0 0 0
NR → W 23.9 (2.9) 26.8 (5.3) 40.7 (7.0) 43.6 (5.5)* 20.4 (2.8) 25.3 (2.1)
NR → R 1.2 (0.4) 0.8 (0.3) 1.0 (0.3) 0.9 (0.5) 2.1 (0.9) 4.4 (0.8)**
R → W 1.2 (0.4) 0.8 (0.3) 1.0 (0.3) 0.9 (0.5) 2.1 (0.9) 4.3 (0.8)**
R → NR 0 0 0 0 0 0
Values (means ± s.e.m.) are calculated for 3 h after administratrion at ZT 12. W, NR, and R represents wake, NREM sleep, and REM sleep, respectively.
*P<0.05 and **P<0.01 for each dose vs. control, one-way ANVA followed by Bonfferoni correction as post-hoc test.
number of transitions between wakefulness and NREM sleep,
while suvorexant did not (Table 1). These findings suggest that
OX1R might have additional effects of increasing wakefulness,
and blocking of OX1R along with OX2R blockade further con-
solidates NREM sleep. This is again consistent with our previous
study showing that ICV orexin-A still increased wakefulness in
OX2R−/− mice (Mieda et al., 2011).
Both C1m and suvorexant showed greater sleep-promoting
effects in mice during the dark period, in which orexin neu-
rons fire rapidly (Lee et al., 2005), than during the light period.
Still, whereas the administration of C1m just prior to onset
of the light phase had only minimal effects on wakefulness,
suvorexant (30mg/kg) was able to significantly decreased wake-
fulness time (Figure 4A) and increase REM sleep time also in
the light period (Figure 4C, Figure S4C). These observations
suggest that DORAs might have a more powerful impact on
sleep/wakefulness states especially during the light period as com-
pared with 2-SORA. This could suggest a role of OX1R in gating
of the transition from NREM sleep to wakefulness during the
resting period. The impact of 1 h of suvorexant on wakefulness
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FIGURE 6 | Number of Fos-positive neurons at 2h after
administration of vehicle and drugs (30mg/kg C1m and suvorexant)
at ZT12 in C57BL/6 mice (n = 6/group). Typical images of Fos
expression in orexin-IR cells in lateral hypothalamic area (A), TH-IR cells
in LC (B), TPH-IR cells in DR (C), and HDC-IR cells in TMN (D). Fos-IR
nucleus-positive cells are calculated as the percentage of orexin-IR cells
(red) with a Fos-IR nucleus (green) in all orexin neurons, TH-IR cells (red)
with a Fos-IR nucleus (green) in all TH-IR cells, TPH-IR cells (red) with a
Fos-IR nucleus (green) in all TPH-IR cells, and HDC-IR cells (red) with a
Fos-IR nucleus (green) in all HDC-IR cells. Data are expressed as
percentage and presented as mean ± s.e.m. ∗p < 0.05, ∗∗p < 0.01 and
∗∗∗p < 0.001. TH, tryptophane hydroxylase; LC, locus coeruleus; TPH,
tryptophan hydroxylase; HDC, histidine decarboxylase; TMN,
tuberomammillary nucleus.
time when administered during the day (Figure S3A) could
be due to more rapid onset of action of suvorexant, because
administration per se has a stimulant effect, and only a com-
pound with a rapid onset of action could show efficacy at that
moment.
We observed an increase of wakefulness in the 6–12 h
time window after the administration of suvorexant at ZT12
(Figure 3A). However, we did not find a rebound increase of
wakefulness in the C1m-administered group (Figure 1A). This
difference is likely the result of the different time periods where
both compounds exert biological activity. Alternatively, blocking
OX1R might lead to more profound wakefulness rebound after
the time of sleep-induction. This mechanism should be addressed
in future studies.
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Orexin−/− and OX2R−/− mice show sleep fragmentation dur-
ing the dark period, which is accompanied by a shorter NREM
episode duration during the dark period (Chemelli et al., 1999;
Willie et al., 2003). Although C1m increased the frequency of
transitions between wakefulness andNREM sleep states (Table 1),
it did not significantly shorten NREM sleep episode duration.
Suvorexant increased the NREM sleep duration and decreased the
frequency of transitions between NREM and REM sleep when it
was administered in the dark period (Figure 5E). The increase
in duration of NREM and REM sleep by DORAs is consis-
tent with the results of previous studies (Winrow et al., 2012).
These observations suggest that acute pharmacological blockade
of OX2R or both receptors increases sleep time, but does not
induce sleep/wakefulness fragmentation, one of the important
characteristics of narcolepsy. These observations suggest that the
sleep/wakefulness fragmentation in narcolepsy might be due to
chronic compensatory processes in narcoleptic animals resulting
from chronic deficiency of orexin signaling (Tsujino et al., 2013).
OX1R and OX2R are distributed differently in the brain.
Histaminergic neurons in the TMN, which strongly express
OX2R, are thought to play an important role in the arousal-
promoting effect of orexin, because the effect of ICV orexin-
A administration is markedly attenuated by the histamine
H1 receptor antagonist pyrilamine and is absent in H1 his-
tamine receptor knockout mice (Huang et al., 2001; Yamanaka
et al., 2002). Mochizuki et al. produced a mouse model in
which a loxP-flanked gene cassette disrupts production of
OX2R, but normal OX2R expression can be restored by Cre
recombinase (Mochizuki et al., 2011). They showed that tar-
geted Cre expression, i.e., focal restoration of OX2R expression,
in the TMN and adjacent regions abrogated fragmentation
of wakefulness in this mouse model, suggesting that the
orexin signaling mediated by OX2R in the TMN and/or
its surrounding area in the posterior hypothalamus is suf-
ficient to prevent sleepiness caused by systemic OX2R defi-
ciency. However, orexins probably promote arousal through
many redundant systems because optogenetic activation of
orexin neurons still promotes wakefulness in mice lacking his-
tamine (Carter et al., 2009), and mice lacking both OX1R
and histamine H1 receptors demonstrate no abnormality of
sleep/wakefulness (Hondo et al., 2010). Our present study further
suggests an additional role of OX1R in promoting and main-
taining wakefulness, and a relatively large impact on REM sleep
amount.
To gain an insight into the mechanisms by which both com-
pounds affect sleep/wakefulness states, we examined the effects
of the compounds on the number of Fos-IR neurons in orexin-
target areas (Figure 6). Compounds were administered at the
start of the dark period. We found that the number of Fos-IR
noradrenergic neurons in the LC was lower in the suvorexant
group as compared with the control and C1m-treated groups
(Figure 6B). This is consistent with the fact that noradrenergic
neurons in the LC exclusively express OX1R (Mieda et al., 2011).
The number of Fos-IR serotonergic neurons in the DR was simi-
larly lower in the suvorexant and C1m groups than in the control
group (Figure 6C). This suggests that orexin mainly excites sero-
tonergic neurons through activation of OX2R, although these
cells also express OX1R (Mieda et al., 2011). We observed that
the number of Fos-IR neurons in histaminergic neurons in the
TMN was lower in both the C1m and suvorexant groups as com-
pared with the control group (Figure 6D), consistent with the
previous observation that these cells only express OX2R (Mieda
et al., 2011). Unexpectedly, we observed that the suvorexant
group showed a larger number of Fos-IR orexin neurons in the
LHA as compared with the control and C1m-treated groups
(Figure 6A), although a previous study suggested that orexin
neurons express OX2R (Yamanaka et al., 2010). The increased
number of Fos-IR orexin neurons in the suvorexant group com-
pared with the control group might have resulted from decreased
activity of monoaminergic neurons, which were shown to send
inhibitory feedback projections to orexin neurons (Sakurai and
Mieda, 2011). Inhibitory feedback mechanisms mediated by
noradrenergic neurons might play a major role in regulation of
orexinergic activity, because C1m did not affect the number of
Fos-IR neurons (Figure 6A). Alternatively, blockade by suvorex-
ant of OX1R-mediated activation of GABAergic interneurons that
send inhibitory projections to orexin neurons might increase the
activity of orexin neurons (Matsuki et al., 2009). The suvorexant-
mediated increase in orexin neuronal activity might be one of the
possible reasons for the rebound wakefulness seen in suvorexant-
administered mice in the latter half of the dark period after
administration at ZT12 (Figure 2A).
To precisely compare the effects of DORA vs. 2-SORA on
sleep/wakefulness states, it would be necessary to compare the
effects at equal free brain concentrations and also to have data
of brain receptor occupancy. Although we do not have such data,
our present results would be useful for further understanding the
characteristics of the effects of DORA and 2-SORA and the roles
of the two orexin receptors in sleep/wakefulness regulation.
CONCLUSION
Given the comparable values of % reduction of wakefulness time
for 6 h after administration of C1m (30mg/kg) and suvorex-
ant (30mg/kg), −17.2% [F(3, 26) = 9.55, p < 0.01] and −17.8%
[F(2, 20) = 3.74, p < 0.05] (Figures 1A, 3A), respectively, C1m,
a newly developed 2-SORA, sufficiently suppressed wakefulness
and promoted sleep with comparable efficacy to that of suvorex-
ant, a potent DORA. However, suvorexant induced more sta-
ble sleep with longer NREM sleep episode duration and fewer
NREM to wakefulness transitions, suggesting that additional
OX1R blockade confers more stable sleep. On the other hand,
C1m showed little effect on REM sleep time while suvorexant sig-
nificantly increased REM sleep time. These results suggest that
the different effects of DORA vs. 2-SORA on orexin-target neu-
rons might reflect differences in the effects of these two drugs on
sleep/wake behavior in mice.
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Figure S1 | Hourly analysis of effects of C1m on basal sleep/wakefulness
states in C57BL/6 mice (n = 6–9/group) after administration at ZT12. C1m
(10, 30, 90mg/kg) and methylcellulose as control were administered per
os at the start of the dark period (t = 0, ZT12). Total time spent in each
state (A–C) and average episode duration of each state (D–F) over 24 h.
Data for the dark and light periods are displayed with light gray and white
backgrounds, respectively. ∗p < 0.05 for 10mg/kg C1m, +p < 0.05 for
30mg/kg C1m, #p < 0.05 for 90mg/kg C1m vs. control, two-way ANOVA
followed by Bonfferoni correction as a post-hoc test. Results are
expressed in minutes and presented as mean ± s.e.m (n = 9 for control,
n = 6 for 10mg/kg C1m, n = 9 for 30mg/kg C1m, n = 6 for
90mg/kg C1m).
Figure S2 | Hourly analysis of effects of C1m on basal sleep/wakefulness
states in C57BL/6 mice (n = 6–7/group) after administration at ZT0. C1m
(10, 30, 90mg/kg) and methylcellulose as control were administered per
os at the start of the dark period (t = 0, ZT0). Total time spent in each
state (A–C) and average episode duration of each state (D–F) over 24 h.
Data for the dark and light periods are displayed with light gray and white
backgrounds, respectively. ∗p < 0.05 for 10mg/kg C1m, +p < 0.05 for
30mg/kg C1m, #p < 0.05 for 90mg/kg C1m vs. control, two-way ANOVA
followed by Bonfferoni correction as a post-hoc test. Results are
expressed in minutes and presented as mean ± s.e.m (n = 7 for control,
n = 7 for 10mg/kg C1m, n = 7 for 30mg/kg C1m, n = 6 for
90mg/kg C1m).
Figure S3 | Hourly analysis of effects of suvorexant on basal
sleep/wakefulness states in C57BL/6 mice (n = 7–9/group) after
administration at ZT12. Suvorexant (10, 30mg/kg) and methylcellulose as
control were administered per os at the start of the dark period (t = 0,
ZT12). Total time spent in each state (A–C) and average episode duration
of each state (D–F) over 24 h. Data for the dark and light periods are
displayed with light gray and white backgrounds, respectively. ∗p < 0.05
for 10mg/kg suvorexant, +p < 0.05 for 30mg/kg suvorexant vs. control,
two-way ANOVA followed by Bonfferoni correction as a post-hoc test.
Results are expressed in minutes and presented as mean ± s.e.m (n = 9
for control, n = 7 for 10mg/kg suvorexant, n = 7 for 30mg/kg suvorexant).
Figure S4 | Hourly analysis of effects of suvorexant on basal
sleep/wakefulness states in C57BL/6 mice (n = 5–7/group) after
administration at ZT0. Suvorexant (10, 30mg/kg) and methylcellulose as
control were administered per os at the start of the dark period (t = 0,
ZT0). Time spent in each state (A–C) and average episode duration of each
state (D–F) over 24 h. Data for the dark and light periods are displayed
with light gray and white backgrounds, respectively. ∗p < 0.05 for
10mg/kg suvorexant, +p < 0.05 for 30mg/kg suvorexant vs. control,
two-way ANOVA followed by Bonfferoni correction as a post-hoc test.
Results are expressed in minutes and presented as mean ±s.e.m. (n = 7
for control, n = 7 for 10mg/kg suvorexant, n = 5 for 30mg/kg suvorexant).
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